| Patents for A61P 17 - Drugs for dermatological disorders (106,455) |
|---|
| 01/17/2002 | WO2002004434A1 Colchinol derivatives as vascular damaging agents |
| 01/17/2002 | WO2002004429A1 Pyrimidine derivatives |
| 01/17/2002 | WO2002004015A1 Polymer-modified bioactive synthetic chemokines, and methods for their manufacture and use |
| 01/17/2002 | WO2002004002A2 Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals and anticancer pharmaceuticals |
| 01/17/2002 | WO2002003945A1 Use of oligosaccharides to stimulate beta-endorphin production |
| 01/17/2002 | WO2002003944A1 Composition comprising a ceramide precursor for improving natural or reconstructed epidermis, resulting skin equivalent |
| 01/17/2002 | WO2002003912A2 Novel c-4 substituted retinoids |
| 01/17/2002 | WO2002003899A1 Method and manufacture of a wound dressing for covering an open wound |
| 01/17/2002 | WO2001058412A3 Extracts from residues left in the production of wine |
| 01/17/2002 | WO2001047950A3 Basolateral sorting signal based on scf peptide and inhibitors thereof |
| 01/17/2002 | WO2001047922A3 Azaindoles |
| 01/17/2002 | WO2001043558A3 Reduced calorie fat compositions |
| 01/17/2002 | WO2001038878A3 Pin1 as a marker for abnormal cell growth |
| 01/17/2002 | WO2001038303A3 Vitamin d analogues |
| 01/17/2002 | WO2001037847A3 Nontoxic vernix compositions and method of producing |
| 01/17/2002 | WO2001035906A3 Personal care articles comprising a hydrophilic conditioning agent exhibiting a defined leaching value |
| 01/17/2002 | WO2001035905A3 Personal care articles comprising cationic polymer coacervate compositions |
| 01/17/2002 | WO2001034175A3 Methods of treating inflammatory bowel disease using cholera toxin b subunit |
| 01/17/2002 | WO2001031051A3 Antisense modulation of protein kinase c-theta expression |
| 01/17/2002 | WO2001030362A3 Ribozyme therapy for the treatment of proliferative skin and eye diseases |
| 01/17/2002 | WO2001022972A3 Immunostimulatory nucleic acids |
| 01/17/2002 | WO2001017565A3 Polyoxyalkylenes conjugates as enzyme inhibitors |
| 01/17/2002 | WO2001016293A3 Dna encoding the human serine protease t |
| 01/17/2002 | WO2001012598A3 METHODS OF INHIBITING BINDING OF β-SHEET FIBRIL TO RAGE AND CONSEQUENCES THEREOF |
| 01/17/2002 | WO2001007471A3 Cell cycle and proliferation proteins |
| 01/17/2002 | WO2000078953A3 Human transport proteins |
| 01/17/2002 | WO2000078952A3 Human rna metabolism proteins (rmep) |
| 01/17/2002 | US20020007075 Neurological disorders including physically damaged nerves and neurodegenerative diseases, and for treating alopecia and promoting hair growth; Alzheimer's, Parkinson's disease; amyotrophic lateral sclerosis |
| 01/17/2002 | US20020007060 Enzyme inhibitors; connective tissue cells; antiarthritic agents; anticarcinogenic agents |
| 01/17/2002 | US20020006951 Solid-state form of celecoxib having enhanced bioavailability |
| 01/17/2002 | US20020006945 Immunology diseases |
| 01/17/2002 | US20020006941 p53 inhibitors and therapeutic use of the same |
| 01/17/2002 | US20020006917 Method of locking 1alpha-OH of vitamin D compounds in axial orientation |
| 01/17/2002 | US20020006913 Maintenance of Dna; reduce damage |
| 01/17/2002 | US20020006906 Novel active agent, composition containing it and use in the cosmetic, dermocosmetic, dermopharmaceutical or pharmaceutical field or on woven or nonwoven supports |
| 01/17/2002 | US20020006654 Isolated cathepsin L type cysteine proteases and reducing intercorneocyte cohesion/promoting desquamation therewith |
| 01/17/2002 | US20020006640 Uteroglobin-like polynucleotides, polypeptides, and antibodies |
| 01/17/2002 | US20020006421 Long-acting, chemical-resistant skin emollients, moisturizers, and strengtheners |
| 01/17/2002 | US20020006420 Use of a 2-amino-alkane polyol as agent for treating skin ageing signs |
| 01/17/2002 | US20020006416 Use of an extract of gaboon resin |
| 01/17/2002 | US20020006410 Method for treating inflammatory diseases using heat shock proteins |
| 01/17/2002 | US20020006383 Promoter of biosynthesis of skin cells |
| 01/17/2002 | DE10031457A1 Verwendung von Flavon-/Flavanon-Derivaten zur systemischen Behandlung von Prophylaxe von UV-induzierten Dermatosen und unerwünschten Langzeitfolgen von UV-Bestrahlungen Use of flavone / flavanone derivatives for the systemic treatment of prevention of UV-induced dermatoses and adverse long-term effects of UV radiation |
| 01/17/2002 | CA2427066A1 Method for the recovery and application of human defensins as biologically active proteins for the treatment of infections and other diseases |
| 01/17/2002 | CA2415547A1 Process for preparing benzoxazin-4-one polymer conjugates |
| 01/17/2002 | CA2414387A1 Drug metabolizing enzymes |
| 01/17/2002 | CA2414219A1 Lipid metabolism molecules |
| 01/17/2002 | CA2412162A1 Chemokine receptor modulators, production and use |
| 01/17/2002 | CA2412150A1 Polymer-modified bioactive synthetic chemokines, and methods for their manufacture and use |
| 01/17/2002 | CA2411160A1 Colchinol derivatives as vascular damaging agents |
| 01/16/2002 | EP1172115A1 Hemostatic soluble cellulose fibers containing coagulating protein for treating wound and process for producing the same |
| 01/16/2002 | EP1172101A1 The use of nimesulide for the treatment of psoriasis and psoriatic arthritis |
| 01/16/2002 | EP1172094A1 Composition, particularly for cosmetics, comprising DHEA and/or precursor or derivative, and at least a compound which increases the synthesis of glycosaminoglycans |
| 01/16/2002 | EP1172093A1 Skin dyeing compositions containing flavylium salt compounds non substituted in position 3 and an organomodified silicone |
| 01/16/2002 | EP1172092A1 Skin dyeing compositions containing at least an uv filter and a non substituted in position 3 flavylium salt |
| 01/16/2002 | EP1172091A1 Skin dyeing compositions containing flavylium salt compounds non substituted in position 3 |
| 01/16/2002 | EP1172090A1 Skin dyeing compositions containing at least a mono or polycarbonyl self-tanning compound and a flavylium salt non substituted in position 3 |
| 01/16/2002 | EP1172087A2 Topical treatment of skin |
| 01/16/2002 | EP1172080A1 Vitamins and mineral salts composition to reduce the hairloss and/or to promote the hairregrowth |
| 01/16/2002 | EP1172077A1 Nanoemulsion containing nonionic polymers |
| 01/16/2002 | EP1171626A1 50 human secreted proteins |
| 01/16/2002 | EP1171599A1 Adipocyte complement related protein homolog zacrp2 |
| 01/16/2002 | EP1171596A1 Synthetic transmembrane components |
| 01/16/2002 | EP1171591A1 48 human secreted proteins |
| 01/16/2002 | EP1171590A1 50 human secreted proteins |
| 01/16/2002 | EP1171579A1 Human tumor necrosis factor receptor tr9 |
| 01/16/2002 | EP1171462A2 49 human secreted proteins |
| 01/16/2002 | EP1171457A1 46 human secreted proteins |
| 01/16/2002 | EP1171444A1 Pyrido-thieno-diazepines, method for the production thereof and pharmaceutical compositions containing said pyrido-thieno-diazepines |
| 01/16/2002 | EP1171442A1 Xanthine derivatives and analogs as cell signalling inhibitors |
| 01/16/2002 | EP1171435A2 Pyrimidine-2-one derivatives as integrin receptor ligands |
| 01/16/2002 | EP1171431A1 Compounds, their preparation and use |
| 01/16/2002 | EP1171425A1 Use of maduraphthalazine derivatives as inhibitors of pro-inflammatory cytokins |
| 01/16/2002 | EP1171422A1 Mmp inhibitor |
| 01/16/2002 | EP1171414A1 Compounds, their preparation and use |
| 01/16/2002 | EP1171155A2 Therapeutic compositions and methods for enhancing angiogenesis |
| 01/16/2002 | EP1171154A2 Uses of mammalian ox2 protein and related reagents |
| 01/16/2002 | EP1171151A1 Thrombospondin-2 and uses thereof |
| 01/16/2002 | EP1171149A1 Inhibition of proteasome function induces programmed cell death in endothelial cells |
| 01/16/2002 | EP1171144A1 Use of tetrahydrocurcuminoids to regulate physiological and pathological events in the skin and mucosa |
| 01/16/2002 | EP1171143A1 Peptide extract of lupine and pharmaceutical or cosmetic or nutritional composition comprising same |
| 01/16/2002 | EP1171140A2 Treatment of hypersensitivity reaction disorders |
| 01/16/2002 | EP1171136A2 Immunomodulating composition for use especially in the treatment of inflammations, infections and surgical adhesions |
| 01/16/2002 | EP1171135A1 6-azaindole compounds as antagonists of gonadotropin releasing hormone |
| 01/16/2002 | EP1171131A1 Medicaments containing inhibitors of cell-volume regulated human kinase h-sgk |
| 01/16/2002 | EP1171130A1 Pharmaceutical compositions containing poly(adp-ribose) glycohydrolase inhibitors and methods of using the same |
| 01/16/2002 | EP1171127A2 Pharmaceutical compositions containing pyridine or pyrimidine derivatives for inhibition of cytokine production and secretion |
| 01/16/2002 | EP1171125A1 6-azaindole compounds as antagonists of gonadotropin releasing hormone |
| 01/16/2002 | EP1171122A1 Pyrrolidine modulators of chemokine receptor activity |
| 01/16/2002 | EP1171120A1 Methods for alleviating discomfort of a hot flash and compositions therefor |
| 01/16/2002 | EP1171115A1 Methods of delivery of cetyl myristoleate |
| 01/16/2002 | EP1171113A1 Compounds useful as phosphotyrosine mimics |
| 01/16/2002 | EP1171093A2 Skin care compositions containing combination of skin care actives |
| 01/16/2002 | EP1171091A1 Pharmaceutical or cosmetic compositions for the local, intradermal application of hormones |
| 01/16/2002 | EP1171089A2 Skin care compositions containing combination of skin care actives |
| 01/16/2002 | EP1171081A2 Skin care compositions containing combination of skin care actives |
| 01/16/2002 | EP1121926A9 Cosmetic preparations containing Waltheria indica extracts |
| 01/16/2002 | EP1093374B1 Hypo-osmotic saline solutions, method for preparing same and medicines based on said solutions |
| 01/16/2002 | EP1014934B1 Use of at least an extract of the genus chrysanthemum for stimulating skin and/or hair pigmentation |
| 01/16/2002 | EP0973495B1 Use of bambara nut seed extract(s) in a cosmetic composition |